Skip to content
A

Ahmed S. Ali

Publications (7)

Phytochemicals against COVID -19, Pharmacological Perspectives: A Systematic Review

Ahmed S. Ali, Ekram A. Saied, Sharifa M. Theeban, Mazen M. Humayran, Assmaa Ahmed Shaker, Mohammed S. Almuhayawi & Abdelbagi Alfadil · Journal of Pharmaceutical Research International · 2021

Background: Many publications discussed the potential role of medicinal plants in the management of COVID-19. However, clinical studies of the efficacy and safety of specified phytochemical(s) are limited. Objectives: To explore the pharmacological profile of specified compounds...

Open access Research Article 10.9734/jpri/2021/v33i53B33678

Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile

Ahmed S. Ali, Mahran S. Abdel-Rahman, Riyadh S. Almalikil, Abir S. Mohamed, Khalid A. Alfaifi, Abdelbabgi El. Fadil, Nagla A. El-Shitany & Huda M. Alkreathy · Journal of Pharmaceutical Research International · 2020

After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning some medications is the best, fastest and most reliable option for treating pati...

Open access Research Article 10.9734/jpri/2020/v32i830468

Interaction of Cyclosporine A with Pomegranate Juice and Its Potential Nephroprotective Effect in Rats

Ahmed S. Ali, Mai A. Abdul Sattar, Hala M. Makki, Soad S. Ali & Ragia H. Ghoneim · Journal of Pharmaceutical Research International · 2019

Objectives: To study the effect of concomitant administering of pomegranate juice orally (PJ) on bioavailability of cyclosporine A (CsA) and independently its potential nephroprotective effect against CsA induced nephrotoxicity. Methods: A- Pharmacokinetic study (PK), Wister rats...

Open access Research Article 10.9734/jpri/2018/v25i330103

Major Adverse Effects Associated with Tacrolimus (Fk506) Based Regimen among Saudi Kidney Transplant Patients

Ahmed S. Ali, Marzog S. Al-Nasser, Mai A. Abdul Sattar, Huda M. Alkreathy, Mohammed N. Al-Amma, Rayan A. Alsulaimani & Ezz H. Abdulfattah · Journal of Pharmaceutical Research International · 2018

Tacrolimus (Fk506)- based immunosuppressant regimen has become the cornerstone in managing kidney transplant patients (KTP) , where it has been used typically used on chronic basis. However, various adverse effects on multiple organ systems are expected and their incidence is dep...

Open access Research Article 10.9734/JPRI/2018/41611

The Wound Healing Potential of 2,3 Dimethylquinoxaline Hydrogel in Rat Excisional Wound Model

Abdelbagi Elfadil, Ahmed S. Ali, Mohammad W. Alrabia, Hamoud Alsamhan, Hind Abdulmajed, Ibrahim Ismail Mohammed Abu, Mohammad Allibaih & Khalid Hussein Bakheit Ahmed · Journal of Pharmaceutical Research International · 2023

Background: 2,3-dimethylquinoxaline (DMQ) is a naturally occurring compound with documented antifungal activity. It showed also good in vitro physicochemical and pharmacokinetic characteristics. Methods: The wound healing activity of 1% DMQ hydrogel in healthy adult male Wister r...

Open access Research Article 10.9734/jpri/2023/v35i87339

In vivo and In vitro Antifungal Activity of 2,3-Dimethylquinoxline

Abdelbagi Alfadil, Hamoud A. Alsamhan, Ahmed S. Ali, Huda M. Alkreathy, Mohammad W. Alrabia & Hani Y. Abdullah · Journal of Pharmaceutical Research International · 2021

Aims: To explore the antifungal activity of 2,3-dimethylquinoxaline. Study Design: A preclinical study of a compound against 10 fungal species. Backgrounds: Severe fungal infections cause significant clinical problem and need more effort to search for new antifungals. Methodology...

Open access Research Article 10.9734/jpri/2021/v33i31A31684

Metformin as an Adjuvant Therapy Attenuates Dextran Sulphate Sodium-induced Acute Colitis in Rats

Rania M. Magadmi, Fahad H. Aljahdali, Mustafa Alsawy, Ahmed S. Ali & Fatemah O. Kamel · Journal of Pharmaceutical Research International · 2020

Aims: In numerous cases, patients with inflammatory bowel diseases (IBDs) are refractory to standard treatment. Sirolimus (SIR) and tacrolimus (TAC) are immunosuppressant drugs with encouraging outcomes. However, they have side effects causing limitations in their use. Metformin...

Open access Research Article 10.9734/jpri/2020/v32i1030496